ES2986327T3 - Compuestos aza bicíclicos como agonistas del receptor muscarínico - Google Patents

Compuestos aza bicíclicos como agonistas del receptor muscarínico Download PDF

Info

Publication number
ES2986327T3
ES2986327T3 ES18179258T ES18179258T ES2986327T3 ES 2986327 T3 ES2986327 T3 ES 2986327T3 ES 18179258 T ES18179258 T ES 18179258T ES 18179258 T ES18179258 T ES 18179258T ES 2986327 T3 ES2986327 T3 ES 2986327T3
Authority
ES
Spain
Prior art keywords
compound
mmol
carboxylate
compounds
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18179258T
Other languages
English (en)
Spanish (es)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Michael Alistair O'brien
Mark Pickworth
Mark David Rackham
Benjamin Gerald Tehan
Barry John Teobald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2986327(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Application granted granted Critical
Publication of ES2986327T3 publication Critical patent/ES2986327T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
ES18179258T 2014-02-06 2015-02-06 Compuestos aza bicíclicos como agonistas del receptor muscarínico Active ES2986327T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2986327T3 true ES2986327T3 (es) 2024-11-11

Family

ID=52465550

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18179258T Active ES2986327T3 (es) 2014-02-06 2015-02-06 Compuestos aza bicíclicos como agonistas del receptor muscarínico
ES15703826.6T Active ES2688548T3 (es) 2014-02-06 2015-02-06 Compuestos aza bicíclicos como agonistas del receptor muscarínico M1

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15703826.6T Active ES2688548T3 (es) 2014-02-06 2015-02-06 Compuestos aza bicíclicos como agonistas del receptor muscarínico M1

Country Status (30)

Country Link
US (6) US9670183B2 (enExample)
EP (3) EP3102568B1 (enExample)
JP (7) JP6479029B2 (enExample)
KR (1) KR102352388B1 (enExample)
CN (2) CN106458986B (enExample)
AU (3) AU2015213900B2 (enExample)
BR (1) BR112016017979B1 (enExample)
CA (1) CA2938169C (enExample)
CL (1) CL2016001983A1 (enExample)
CY (1) CY1120834T1 (enExample)
DK (2) DK3102568T3 (enExample)
ES (2) ES2986327T3 (enExample)
FI (1) FI3406609T3 (enExample)
HR (2) HRP20241145T1 (enExample)
HU (1) HUE068301T2 (enExample)
IL (1) IL247117B (enExample)
LT (2) LT3406609T (enExample)
MX (2) MX371529B (enExample)
NZ (1) NZ723103A (enExample)
PH (1) PH12016501570B1 (enExample)
PL (2) PL3102568T3 (enExample)
PT (2) PT3406609T (enExample)
RS (2) RS65894B1 (enExample)
RU (1) RU2685230C2 (enExample)
SA (1) SA516371614B1 (enExample)
SG (1) SG11201606269WA (enExample)
SI (2) SI3406609T1 (enExample)
SM (1) SMT202400446T1 (enExample)
UA (1) UA122121C2 (enExample)
WO (1) WO2015118342A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2780015T (pt) 2011-11-18 2017-03-23 Heptares Therapeutics Ltd Agonistas de recetor muscarínico m1
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
MX371529B (es) 2014-02-06 2020-01-31 Heptares Therapeutics Ltd Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3261639B1 (en) 2015-02-27 2022-08-24 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
US20200369611A1 (en) * 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN112154145B (zh) 2018-03-23 2023-10-17 辉瑞大药厂 哌嗪氮杂螺衍生物
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN119390705A (zh) * 2019-10-09 2025-02-07 诺华股份有限公司 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
US11548865B2 (en) * 2019-10-09 2023-01-10 Novartis Ag 2-azaspiro[3.4]octane derivatives as M4 agonists
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
US20230129359A1 (en) * 2020-02-05 2023-04-27 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
EP4508045B1 (en) 2022-08-04 2025-10-01 Nxera Pharma UK Limited Citrate salt forms of a muscarinic receptor agonist
CN120344513A (zh) * 2022-09-16 2025-07-18 赛尔维治疗有限责任公司 M4活化剂/调节剂及其用途
CN120641409A (zh) * 2023-01-12 2025-09-12 赛尔维治疗有限责任公司 作为m4活化剂/调节剂的螺衍生物及其用途
WO2024158645A1 (en) 2023-01-24 2024-08-02 Neurocrine Biosciences, Inc. Deuterated compounds
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025030095A1 (en) 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2002085890A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
MXPA06013842A (es) * 2004-05-28 2007-03-01 Vertex Pharma Moduladores de receptores muscarinicos.
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
JP2009521483A (ja) 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP1987034B1 (en) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
US20090062537A1 (en) * 2006-03-03 2009-03-05 Kwangho Lee N-Formyl Hydrozyamine Compounds
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2010049146A1 (en) 2008-10-29 2010-05-06 Grünenthal GmbH Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
PT2780015T (pt) * 2011-11-18 2017-03-23 Heptares Therapeutics Ltd Agonistas de recetor muscarínico m1
EP2897948B1 (en) * 2012-09-18 2016-08-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
BR112015027527A2 (pt) 2013-04-30 2017-07-25 Glaxosmithkline Ip No 2 Ltd intensificador de inibidores do homólogo zeste 2
JP6581100B2 (ja) 2014-02-06 2019-09-25 リボサイエンス・エルエルシー インフルエンザｒｎａ複製の阻害剤としての４’−ジフルオロメチル置換ヌクレオシド誘導体
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
MX371529B (es) * 2014-02-06 2020-01-31 Heptares Therapeutics Ltd Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
EA033697B1 (ru) 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
DK3447050T3 (da) 2014-09-19 2020-03-09 Forma Therapeutics Inc Pyridin-2(1h)-on-quinolinderivater som mutant-isocitrat dehydrogenaseinhibitorer
EP3194379A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors

Also Published As

Publication number Publication date
AU2019201579A1 (en) 2019-03-28
US10385039B2 (en) 2019-08-20
MX2020001236A (es) 2022-06-30
CA2938169C (en) 2022-03-15
US20170240530A1 (en) 2017-08-24
JP2019077725A (ja) 2019-05-23
AU2020277225A1 (en) 2020-12-24
JP7652833B2 (ja) 2025-03-27
UA122121C2 (uk) 2020-09-25
CN109851610A (zh) 2019-06-07
JP2023087045A (ja) 2023-06-22
EP3102568A1 (en) 2016-12-14
PT3102568T (pt) 2018-10-24
US20170015650A1 (en) 2017-01-19
SI3406609T1 (sl) 2024-10-30
CL2016001983A1 (es) 2017-06-23
JP6774513B2 (ja) 2020-10-28
HK1231473A1 (en) 2017-12-22
JP6479029B2 (ja) 2019-03-06
HRP20241145T1 (hr) 2024-11-22
US20190112294A1 (en) 2019-04-18
JP7652832B2 (ja) 2025-03-27
US20200325118A1 (en) 2020-10-15
BR112016017979A2 (enExample) 2017-08-08
SMT202400446T1 (it) 2024-11-15
MX2016010322A (es) 2017-04-27
CN109851610B (zh) 2021-09-21
DK3102568T3 (en) 2018-10-08
DK3406609T3 (da) 2024-08-26
EP3102568B1 (en) 2018-06-27
SI3102568T1 (sl) 2018-11-30
WO2015118342A8 (en) 2016-06-30
NZ723103A (en) 2022-09-30
FI3406609T3 (fi) 2024-09-10
AU2015213900B2 (en) 2018-12-13
EP4413985A3 (en) 2024-10-23
US20190337925A1 (en) 2019-11-07
WO2015118342A1 (en) 2015-08-13
RS65894B1 (sr) 2024-09-30
JP2021006571A (ja) 2021-01-21
JP2023073504A (ja) 2023-05-25
PH12016501570A1 (en) 2016-10-03
JP2023087046A (ja) 2023-06-22
BR112016017979B1 (pt) 2022-08-02
CN106458986A (zh) 2017-02-22
KR20160129014A (ko) 2016-11-08
US9926297B2 (en) 2018-03-27
US10196380B2 (en) 2019-02-05
US10961225B2 (en) 2021-03-30
KR102352388B1 (ko) 2022-01-17
IL247117A0 (en) 2016-09-29
PH12016501570B1 (en) 2016-10-03
US10689368B2 (en) 2020-06-23
PL3406609T3 (pl) 2024-11-25
JP7652829B2 (ja) 2025-03-27
EP3406609A1 (en) 2018-11-28
RU2685230C2 (ru) 2019-04-17
JP2025085736A (ja) 2025-06-05
CY1120834T1 (el) 2019-12-11
AU2015213900A1 (en) 2016-08-11
HUE068301T2 (hu) 2024-12-28
SG11201606269WA (en) 2016-09-29
US9670183B2 (en) 2017-06-06
JP2017505323A (ja) 2017-02-16
ES2688548T3 (es) 2018-11-05
MX371529B (es) 2020-01-31
EP3406609B1 (en) 2024-06-26
CN106458986B (zh) 2019-01-04
PL3102568T3 (pl) 2019-01-31
IL247117B (en) 2021-03-25
CA2938169A1 (en) 2015-08-13
EP4413985A2 (en) 2024-08-14
RS57843B1 (sr) 2018-12-31
PT3406609T (pt) 2024-09-17
MX393637B (es) 2025-03-11
RU2016133684A3 (enExample) 2018-08-31
AU2019201579B2 (en) 2020-08-27
RU2016133684A (ru) 2018-03-14
LT3406609T (lt) 2024-09-25
US20180179184A1 (en) 2018-06-28
HRP20181499T1 (hr) 2018-11-30
LT3102568T (lt) 2018-11-12
SA516371614B1 (ar) 2019-10-30

Similar Documents

Publication Publication Date Title
ES2986327T3 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico
ES2980578T3 (es) Agonistas muscarínicos
ES2894855T3 (es) Agonistas muscarínicos
ES2852753T3 (es) Compuestos espirocíclicos como agonistas del receptor muscarínico M1 y/o M4
ES2894637T3 (es) Agonistas muscarínicos
ES2804774T3 (es) Compuestos de oxima como agonistas del receptor muscarínico M1 y/o M4
ES2872378T3 (es) Agonistas de receptores muscarínicos
DK2897948T3 (en) BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
ES2976504T3 (es) Derivados de quinolinona y benzoxazina como agonistas de los receptores muscarínicos M1 y/o M4
ES2619829T3 (es) Agonistas del receptor muscarínico M1
ES2984420T3 (es) Compuestos con puente como agonistas del receptor muscarínico M1 y/o M4
CN112585135B (zh) 作为毒蕈碱m1和/或m4受体的激动剂的噁二唑
HK1250138B (en) Muscarinic agonists
HK1231382B (en) Muscarinic receptor agonists